linjc16/ctgov huggingface dataset:
Poor In Vitro Fertilisation Outcomes in Genital Tuberculosis - Case Report

Study Overview
=================
Brief Summary
-----------------
This is a case series that highlights the challenges in instituting in vitro fertilisation (IVF) treatment amongs genital tuberculosis patients.

Detailed Description
-----------------
In this case series, the investigators recruited patients undergoing IVF treatment previously diagnosed with TB between 01/01/2014 and 30/06/2021. Patients were recruited at the beginning of their IVF treatments. Total sampling was employed for this study.

Official Title
-----------------
Poor In Vitro Fertilisation Outcomes in Genital Tuberculosis - Case Report

Conditions
-----------------
Tuberculosis, Female Genital, Fertility Disorders

Intervention / Treatment
-----------------
* Other: In vitro fertilisation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with confirmed genital tuberculosis enrolling in in vitro fertilisation treatment Exclusion Criteria: patients not confirmed to having genital tuberculosis
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: In vitro fertilisation|In vitro fertilisation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Live birth rate | the number of live births divided by the number of patients recruited | 9 months of gestation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | the number of clinical pregnancies divided by the number of patients recruited | 9 months of gestation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
In vitro fertilisation, Genital tuberculosis
Vitamin D Supplementation and Respiratory Index of Severity in Children (RISC) in Pneumonia

Study Overview
=================
Brief Summary
-----------------
Childhood deaths from pneumonia is almost 2000 times higher in developing countries than in developed countries. In 1970, pneumonia was responsible for 9% of all deaths in children under 5 years. This rate was 2% in 2007. Some studies have shown that supplementing with vitamin D reduces disease of the respiratory tract infection. Some other studies have shown anti-inflammatory effect of vitamin D in cell lines. Studies about the role of vitamin D supplementation in pneumonia in children are inadequate to conclude about its role. The aim of this study is to determine the efficacy of vitamin D supplementation in Respiratory Index of Severity in Children (RISC) hospitalized clinical outcomes of hospitalized patients with community-acquired pneumonia.

Official Title
-----------------
The Effects of Vitamin D Supplementation in Respiratory Index of Severity in Children (RISC) of Hospitalized Patients With Community-acquired Pneumonia

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Drug: Vitamin D3
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Aged between 2 months to 6 years Definite diagnosis of pneumonia Exclusion criteria Immunocompromised patients Airway hypersensitivity or asthma allergies nasal polyps Using inhaled medications to one month prior to the study Receiving high doses of vitamin D Avoiding to complete informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D3 (Low dose)<br>vitamin D at a dose of 50,000 IU per day for 2 days | Drug: Vitamin D3<br>* vitamin D at a dose of 50,000 IU per day for 2 days<br>* Other names: cholecalciferol;|
| Placebo Comparator: Placebo<br>Placebo (same size and shape) for 2 days | Drug: Placebo<br>* Placebo for 2 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory Index of Severity in Children (RISC) | For determining severity of pneumonia, RISC (Respiratory Index of Severity in Children) scoring system was used, including oxygen saturation, chest retraction, wheezing and refusal to feed, and also contains standards growth (weight for age). | through study completion, an average of 4 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospitalization | Duration of hospitalization of the patient | through study completion, an average of 4 days |
Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Surgery

Study Overview
=================
Brief Summary
-----------------
To compare the safety/efficacy of the robotic-assisted lobectomy/segmentectomy (RAL/S) with the video-assisted lobectomy/segmentectomy (VAL/S) for lung resection. Video-assisted lobectomy/segmentectomy (VAL/S) for lung resection is divided into uniport group and multiple- port group.

Official Title
-----------------
Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Surgery

Conditions
-----------------
Lung Diseases, Surgery

Intervention / Treatment
-----------------
* Procedure: robotic surgery
* Procedure: uniport surgery
* Procedure: multiple- port surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good cardio- pulmonary function to tolerate surgery; minimaly invasive surgery for lobectomy or segmentectomy or sleeve lobectomy; Exclusion Criteria: cardio- pulmonary function is not good enough to tolerate surgery; huge tumor or extensive adhesion in thoracic cavity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: robotic surgery group<br>minimally invasive lung surgery using the Davinci robotic system to assist. | Procedure: robotic surgery<br>* minimally invasive surgery using the Davinci robotic system<br>|
| Active Comparator: uniport surgery group<br>VATS minimally invasive lung surgery under the uniportal status. | Procedure: uniport surgery<br>* VATS minimally invasive surgery under the uniportal status<br>|
| Active Comparator: multiple- port surgery group<br>VATS minimally invasive lung surgery under the multiple- port status. | Procedure: multiple- port surgery<br>* VATS minimally invasive surgery under the multiple- port status<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | incidence rate | 30 days after surgery | 
| conversion rate to open surgery | incidence rate | during surgery | 
| postoperative complications | incidence rate | within 7 days after surgery | 
| operation time | minutes | within 180 minutes | 
| duration of hospitalization | days | within 7 days after surgery | 
| days to tube removal | days | within 7 days after surgery | 
| retrieved lymph node | amount | within 1 days after surgery | 
| retrieved lymph node station | amount | within 1 days after surgery | 
| short- term PFS | proportion | 3 years | 
| short- term overall survival | proportion | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
robotic surgery, VATS, uniport, multiport
The Effects of Body Contouring: Abdominoplasty and Liposuction

Study Overview
=================
Brief Summary
-----------------
The data regarding the effects of aesthetic body contouring is insufficient. Poor results may related to preoperative psychological distress. Studies regarding eating disorder symptoms are lacking. Therefore studies using standardized and validated are needed. We decided to prospectively study quality of life, psychological distress, and eating disorder symptoms in body contouring (abdominoplasty or liposuction) patient populations. Used questionnaires are 15D quality of life, Raitasalo's modification of the Beck Inventory, and the Eating Disorder Inventory. We hypothesize that aesthetic body contouring plastic surgery has notable quality of life effects.

Official Title
-----------------
Body Contouring - the Analysis of Non-invasive and Invasive Methods and Their Interventional Effects on Quality of Life

Conditions
-----------------
Rectus Muscle Diastasis, Subcutaneous Abdominal Fat, Abdominal Skin Elasticity, Unpleasant Body Contour

Intervention / Treatment
-----------------
* Procedure: Abdominoplasty and liposuction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients requesting body contouring surgery Exclusion Criteria: previous abdominal aesthetic surgery, simultaneous other aesthetic surgery at the same time

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Body contouring surgery<br> | Procedure: Abdominoplasty and liposuction<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | 15D quality of life questionnaire RBDI mood questionnaire Eating Disorder Inventory questionnaire | 6 months |
Statin Intolerance in Patients With Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Patients with acute coronary syndrome (MI, NSTEMI, USAP) will be included. They will be screened for statin intolernace for 6 months.

Official Title
-----------------
Statin Intolerance in Patients With Myocardial Infarction

Conditions
-----------------
Statin Adverse Reaction

Intervention / Treatment
-----------------
* Diagnostic Test: Statin intolerance test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute coronary syndrome Exclusion Criteria: Being on statin, having statin related side effects

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Statin intolerance test|Statin intolerance test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Statin intolerance | Number (percentage) of patients with statin intolerance | 6 months |
Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to: make p16INK4A as a cervical cancer screening of tumor markers, cytology improve existing diagnostic sensitivity, specificity, repeatability and validity, so as to effectively prompted the early discovery and diagnosis of cervical cancer. reduce screening costs, screening and benefits into quantitative evaluation, for our country to develop cervical cancer prevention and control strategy to provide a reliable theoretical basis.

Detailed Description
-----------------
To carry out large-scale prospective randomized controlled clinical study to evaluate the cytological molecular markers Detect + P16INK4A methods of screening accuracy and reliability, as well as the screening method of the biological effects. Markov set up mathematical model of screening tests to quantify the inputs and the evaluation proceeds. With a view to optimize and perfect a simple, convenient, practical and efficient program of cervical cancer screening.

Official Title
-----------------
Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis

Conditions
-----------------
Cervical Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Married women aged 25 to 65-year-old with risk factors No tumor and pelvic radiation therapy history Non-pregnant women at present

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Molecular Markers, Cervical Cancer, Screening, Makov
Expired Propofol in Low Back Surgery

Study Overview
=================
Brief Summary
-----------------
Edmon (BBraun, Germany) is a portable, commercially available device for measurement of propofol in exhaled air. The study will aim at evaluating the sensitivity and specificity of such exhaled propofol values compared with plasma propofol and measures of anaesthetic and antinociceptive effect.

Detailed Description
-----------------
Elective low-back surgery patients will be induced for general intubation anesthesia with propofol and remifentanil. After induction a 20 min period of stable propofol infusion only will be established before start of surgery. The patients will be monitored for exhaled propofol, plasma propofol (blood samples), continous frontal EEG, Bispectral Index (BIS), skin conductance, estimated (computer based) concentrations of plasma and effect site propofol, and skin conductance. After start of surgery (with ongoing propofol and restart of remifentanil TCI) the monitoring will continue in order to explore these relationships further.

Official Title
-----------------
Propofol Measurement in Expiration Air and Monitoring of EEG and Pain in Patients Undergoing Low Back Surgery

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Device: Edmon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective patients scheduled for low-back surgery BMI between 20 -32 kg/m2 ASA I-II Written informed concent Exclusion Criteria: Contraindication to propofol TCI Use of psychopharmaco or neurologic disease Pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: The intervention is to have patients in 20 min stable anaesthesia before start of surgery in order to validate the use of exhaled propofol versus pharmakokinetic modelling and measured plasma concentration
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Edmon arm<br> | Device: Edmon<br>* Exhaled air will be analyzed for propofol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exhaled air versus plasma concentration |  | per-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG recording | EEG will be recorded and compared with plasma propofol, exhaled propofol and BIS | per-operative | 
| Exhaled propofol 2 | Exhaled propofol versus dose given, estimated plasma concentration, estimated effect site concentration | per-operative | 
| Nociceptive stimulation | Skin conductance versus plasma and exhaled propofol concentration | per-operative |
Effects of Selective Laser Trabeculoplasty

Study Overview
=================
Brief Summary
-----------------
Primary objective is to evaluate the effect of selective laser trabeculoplasty (SLT) on the diurnal intraocular pressure variation in open-angle glaucoma patients (OAG).

Detailed Description
-----------------
This is a prospective observational study of OAG patients undergoing selective laser trabeculoplasty at the University of Kentucky Chandler Medical Center. The patients will be recruited over 12 months. Study will include 3 visits: pre-laser visit, visit for laser treatment and post-laser visit. All visits will occur within a 3-month period.

Official Title
-----------------
Effect of Selective Laser Trabeculoplasty (SLT) on Diurnal Intraocular Pressure in Open-Angle Glaucoma Patients on Medical Treatment

Conditions
-----------------
Glaucoma

Intervention / Treatment
-----------------
* Procedure: Surgery
* Procedure: Selective Laser Trabeculoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have the diagnosis of open angle glaucoma Subjects who are able to speak and understand English and provide meaningful written informed consent, Subjects who are willing and able to comply with all testing and requirements defined in the protocol and willing and able to comply with all required study visits. Exclusion Criteria: Subjects with previous laser treatment or intraocular surgery, Subjects with history of ocular inflammation and with history of previous ocular trauma.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| laser trabeculoplasty<br>Subjects with POAG and on medical treatment who are undergoing SLT | Procedure: Surgery<br>* Selective Laser Trabeculoplasty for glaucoma<br>* Other names: Selective Laser Trabeculoplasty;Procedure: Selective Laser Trabeculoplasty<br>* Glaucoma Treatment<br>* Other names: SLT;|
| Surgery<br>Glaucoma laser treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effect of selective laser trabeculoplasty on the diurnal intraocular pressure variation in OAG patients. |  | Three years |
Impact of Predictive Genetic Testing

Study Overview
=================
Brief Summary
-----------------
Analysing Impact of preemptive genetic testing on quality of life, physical activity and eating behavior at baseline and 3 months after testing.

Official Title
-----------------
Impact of Predictive Genetic Testing on Quality of Life and Health-related Behaviour

Conditions
-----------------
Genetic Testing, Quality of Life, Physical Activity

Intervention / Treatment
-----------------
* Diagnostic Test: Routine check up including genetic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years informed consent for genetic testing informed consent for study participation Exclusion Criteria: Age <18 years renal replacement dependency pregnancy active cancer disease no informed consent for genetic testing or study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life assessed by the SF-36 questionnaire [followed by its scale information in the Description] | Short form (36) (SF-36) questionnaire evaluates health related quality of life (Scale 0-100) | 3 months | 
| Physical activity assessed by the IPAQ questionnaire [followed by its scale information in the Description] | International Physical Activity Questionnaire (IPAQ) evaluates physical activity in MET(metabolic equivalent)/min/week | 3 months | 
| Eating behavior assessed by the modified LEI questionnaire [followed by its scale information in the Description] | The modified Luzerner Ernaehrungs Index (LEI) questionnaire evaluates eating behavior at lunch (Scale 1-4 per item; 1=never; 4=daily) | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with check up and genetic testing: Likert scale (1-10) | Likert scale (1-10) | 3 months |